Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from diabetes

Eli Lilly To Raise Mounjaro Price In UK, Expands Obesity Drug Push In India

Eli Lilly and Co. (NYSE:LLY) will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom, while expanding its market presence in India with a new injector pen.

Benzinga

Diabetic man produces his own insulin after gene-edited cell transplant

The new proof-of-concept study points a way to curing diabetes without the need for immune-suppressing drugs.

LiveScience

Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, including the widely used GLP-1 medications Mounjaro and Zepbound for diabetes and weight loss.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

The lifestyle medicine that could clear menopausal brain fog

Lifestyle medicine uses interventions to prevent and manage chronic conditions such as heart disease, diabetes and dementia

The Independent UK

Study links weight-loss drugs to serious eye conditions and vision loss

Researchers suggest all diabetes patients on weight-loss drugs should be regularly screened and monitored for potential eye complications

The Independent UK

Ozempic and other weight-loss drugs linked to rare but serious eye conditions

Drugs such as Ozempic, Wegovy and Mounjaro (known as semaglutide and tirzepatide) have changed the way clinicians manage diabetes and obesity around the world.

The Conversation

Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly

Trump’s plan to cover weight loss drugs under Medicaid programs and Medicare Part D plans to could be a major tailwind for LLY and NVO, despite tarrif threats.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

The ‘small, sustainable changes’ that support your long-term health

IN FULL

The Independent UK

10 Foods That Help Burn Belly Fat Naturally

Stubborn belly fat, also known as visceral fat, is more than just a cosmetic concern; it’s a key risk factor for serious health issues like heart disease and type 2 diabetes. While spot reduction is a myth, you can significantly reduce abdominal fat by adopting a healthy lifestyle that includes…

Budget and the Bees

Portugal tightens rules on weight loss drug prescriptions to prevent misuse

Doctors from only four medical specialties will be able to write prescriptions for injectable drugs that are used to treat type 2 diabetes and obesity but are also popular for weight loss.

Euronews

The easy food swaps you should make today to reduce the risk of type 2 diabetes

People who eat French fries three times a week face a 20 per cent greater risk of developing diabetes

The Independent UK

Insulet Peer Tandem Diabetes Underwhelming Earnings, Dull Outlook Drags Stock

Tandem Diabetes Care Inc.’s (NASDAQ:TNDM) stock plunged on Thursday after the company cut its annual guidance.

Benzinga

This Blue-Chip Stock Is Cooking Up a Major Growth Catalyst

Eli Lilly is poised for a major boost as new data shows its diabetes drug Mounjaro offers heart health benefits, potentially making it the top choice for patients with Type 2 diabetes.

Barchart

New weight loss pill more ‘tolerable’ than jabs shown to be effective in key trial

The tablet could be a cheaper and more convenient alternative to injections

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

High demand expected for new daily weight loss pill

The tablet could be a cheaper and more convenient alternative to injections.

The Independent UK

‘Shock’ as study reveals how weight-loss pill stacks up against injections

Shares in a pharmaceutical company plummeted after the results were made public

Benzinga

Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Thursday.

The Independent UK

Just three weekly servings of popular snack could raise diabetes risk by 20%

IN FULL

Get all your
news in one place.

100's of premium titles.
One news app.

Euronews

Potatoes could raise your risk of type 2 diabetes. But how you prepare them matters, study finds

Eating more potatoes was tied to a higher risk of type 2 diabetes risks in a study that spanned three decades – and French fries were the main culprit.

The Independent UK

Hold the fries! How your favorite salty side can increase your risk of type 2 diabetes

The study found eating three servings of fries a week could increase your risk of developing type 2 diabetes by 20 percent

The Guardian - UK

Eating chips three times a week raises type 2 diabetes risk by 20%, study finds

Baking, boiling or mashing potatoes raises risk by 5% and replacing with whole grains lowers risk significantly

The Independent UK

Eating fries over boiled potatoes increases type 2 diabetes risk – study

But wholegrain foods remained the best option to reduce risk, experts said.

The Guardian - UK

Sales of Novo Nordisk’s diabetes drugs including Ozempic slow sharply

Danish company to cut costs and consider layoffs after competition from Mounjaro and the copycat market

Benzinga

Bryan Johnson Spent Millions To Be 18 Again—Says Novo Nordisk's Ozempic Anti-Aging Hype Is Misleading: 'Data Is Not There'

Tech entrepreneur Bryan Johnson, who spends $2 million annually on anti-aging treatments, refutes claims that Novo Nordisk AS‘s (NYSE:NVO) Ozempic demonstrates anti-aging properties. Johnson disputed a post on social platform X suggesting the diabetes drug reverses biological aging by 3.1 years.

Benzinga

4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study

Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) are currently up over 20.6% after the company released positive results from its Spectra trial.

1 … 20 21 22 23

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.